Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Gross Profit (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Gross Profit for 8 consecutive years, with $787.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 27.41% year-over-year to $787.9 million, compared with a TTM value of $2.8 billion through Dec 2025, up 20.98%, and an annual FY2025 reading of $2.8 billion, up 20.98% over the prior year.
  • Gross Profit was $787.9 million for Q4 2025 at Neurocrine Biosciences, up from $780.9 million in the prior quarter.
  • Across five years, Gross Profit topped out at $787.9 million in Q4 2025 and bottomed at $11.9 million in Q2 2021.
  • Average Gross Profit over 4 years is $506.6 million, with a median of $563.4 million recorded in 2025.
  • The sharpest move saw Gross Profit crashed 96.03% in 2021, then rose 27.41% in 2025.
  • Year by year, Gross Profit stood at $291.8 million in 2021, then skyrocketed by 73.65% to $506.7 million in 2023, then grew by 22.04% to $618.4 million in 2024, then grew by 27.41% to $787.9 million in 2025.
  • Business Quant data shows Gross Profit for NBIX at $787.9 million in Q4 2025, $780.9 million in Q3 2025, and $676.2 million in Q2 2025.